ICH E6(R3) is now effective in the EU, marking a pivotal shift in clinical trial oversight. This issue breaks down what it means and how to stay ahead.
TRI’s reimagined OPRA-CM platform delivers on the true promise of RBQM, cutting through complexity to enable smarter, faster, and more focused centralized monitoring.
From Vancouver to London, this edition highlights must-attend RBQM events that offer fresh insights, regulatory updates, and real-world strategies to elevate your clinical trial oversight.
We’re heading to Brussels for SCDM 2025 EMEA! Visit TRI at Booth 21 to discover how our reimagined OPRA-CM platform is transforming centralized monitoring and driving RBQM success.